Suppr超能文献

用动物正电子发射断层扫描(PET)评估[11C]SA5845和[11C]SA4503用于肿瘤中σ受体成像的情况。

Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET.

作者信息

Kawamura Kazunori, Kubota Kazuo, Kobayashi Tadayuki, Elsinga Philip H, Ono Mayumi, Maeda Minoru, Ishiwata Kiichi

机构信息

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Naka-cho 1-1, Itabashi-ku, Tokyo 173-0022, Japan.

出版信息

Ann Nucl Med. 2005 Dec;19(8):701-9. doi: 10.1007/BF02985120.

Abstract

Sigma receptors are expressed in a wide variety of tumor cell lines, and are expressed in proliferating cells. A radioligand for the visualization of sigma receptors could be useful for selective detection of primary tumors and their metastases, and for non-invasive assessment of tumor proliferative status. To this end we evaluated two sigma receptor ligands, [11C]SA5845 and [11C]SA4503. In an in vitro study, AH109A hepatoma showed moderate densities of sigma1 and sigma2 receptors, and VX-2 carcinoma showed a high density of sigma2 receptors: Bmax (fmol/mg protein) for sigma1 vs. sigma2, 1,700 vs. 1,200 for AH109A hepatoma and 800 vs. 10,000 for VX-2 carcinoma. In a cell growth assay in vitro, neither SA5845 nor SA4503 (<10 microM) showed any inhibitory effect on proliferation of the AH109A hepatoma cells. In rats, the uptake of [11C]SA5845 and [11C]SA4503 in AH109A tissues was accumulated over the first 60 minutes; however, the uptake of both tracers increased by co-injection with haloperidol as a sigma receptor ligand. On the other hand, in the PET studies of rabbits, the uptake of [11C]SA5845 in the VX-2 carcinoma was relatively higher than that of [11C]SA4503, because of a much higher density of sigma2 receptors compared to sigma1 receptors in the VX-2 tissue, and the uptake of both tracers in the VX-2 tissue was decreased by carrier-loading and pre-treatment with haloperidol ([11C]SA5845, 53% and 26%, respectively; [11C]SA4503, 41% and 22%, respectively at 30 minutes after injection). Therefore, [11C]SA5845 and [11C]SA4503 may be potential ligands for PET imaging of sigma receptor-rich tumors.

摘要

σ受体在多种肿瘤细胞系中表达,并在增殖细胞中表达。用于可视化σ受体的放射性配体可能有助于原发性肿瘤及其转移灶的选择性检测,以及肿瘤增殖状态的无创评估。为此,我们评估了两种σ受体配体,[11C]SA5845和[11C]SA4503。在一项体外研究中,AH109A肝癌显示出中等密度的σ1和σ2受体,VX-2癌显示出高密度的σ2受体:AH109A肝癌的σ1与σ2的Bmax(fmol/mg蛋白)分别为1700和1200,VX-2癌为800和10000。在体外细胞生长试验中,SA5845和SA4503(<10μM)均未对AH109A肝癌细胞的增殖显示出任何抑制作用。在大鼠中,[11C]SA5845和[11C]SA4503在AH109A组织中的摄取在最初60分钟内积累;然而,作为σ受体配体与氟哌啶醇共同注射时,两种示踪剂的摄取均增加。另一方面,在兔的PET研究中,[11C]SA5845在VX-2癌中的摄取相对高于[11C]SA4503,这是因为VX-2组织中σ2受体的密度比σ1受体高得多,并且通过载体负载和氟哌啶醇预处理后,VX-2组织中两种示踪剂的摄取均降低([11C]SA5845分别在注射后30分钟时降低53%和26%;[11C]SA4503分别降低41%和22%)。因此,[11C]SA5845和[11C]SA4503可能是富含σ受体肿瘤PET成像的潜在配体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验